Fundraising FoxKdT Ventures — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Faeth Therapeutics is a clinical-stage oncology company developing therapies that inhibit multiple nodes of the PI3K/AKT/mTOR (PAM) pathway.
BiotechHealthtechAustin, US
Anand Parikh(Executive Officer, Director, Promoter)inOliver Maddocks(Executive Officer, Director)inChristopher W. Gerry(President and General Counsel)
BoardAlex Morgan(Director)inJayson Dallas(Director)Robert Gould(Director)
Co-investorsAble PartnersAgFunderAtacama VenturesCota CapitalFuture VenturesiSelect Fund+7 more
MacroCycle uses a proprietary chemical process called SolvoGenesis, based on solvent systems and macrocyclic chemistry, to convert textile waste into pure polyester resin at low cost.
Circular EconomyCleantechNew MaterialsCambridge, US
Stwart Peña Feliz(Executive Officer, Director)inJan-Georg Rosenboom(Executive Officer, Director)in
BoardCatia Cesari(Director)Temple Fennell(Director)in
Co-investorsCircular Innovation FundCollaborative FundNeotribe VenturesVolta CircleClean Energy VentureClean Energy Ventures+2 more
Skeletalis is developing OASIS, a targeted small-molecule platform for musculoskeletal and bone health that concentrates therapy at sites of active bone loss while preserving the body's natural bone remodeling.
BiotechDeep TechHealthtech
Syenex provides cell delivery technologies and contract development services for therapeutic cell engineering, serving biopharmaceutical companies developing cell-based therapies.
BiotechDeep TechMedical DevicesEvanston, US
John D. Rosanelli(Executive Officer, Director)
Co-investorsAlleyCorpLightbankAlley Robotics Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.